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PREVENTION OF MURINE COLLAGEN-INDUCED ARTHRITIS
IN THE KNEE AND IPSILATERAL PAW 
BY LOCAL EXPRESSION OF HUMAN INTERLEUKIN-1 RECEPTOR
ANTAGONIST PROTEIN IN THE KNEE
ANDREW C. BAKKER, LEO A. B. JOOSTEN, ONNO J. ARNTZ, MONIQUE M. A. HELSEN,
ALISON M. BENDELE, FONS A. J. v a n  d e  LOO, and WIM B. v a n  d e n  BERG
Objective. To determine the efficacy of local hu­
man interleukin-1 receptor antagonist (HuIL-IRa) gene 
therapy in murine collagen-induced arthritis (CIA).
Methods. DBA/1 mice were immunized against 
bovine type II collagen. Before the onset of arthritis, 
NIH/3T3 fibroblasts transfected with pMFG-IRAP were 
transplanted into the knee cavity. Normal NIH/3T3 cells 
served as controls. Paws were evaluated macroscopically 
for redness, swelling, and deformities during the course 
of arthritis. Swelling of the knee joints was measured by 
external gamma counting of 99mtechnetium accumula­
tion in the joint. Paws and knee joints were dissected 
and processed for histologic studies to evaluate inflam­
mation and cartilage destruction.
Results. The NIH/3T3 fibroblasts survived in the 
joint cavity of DBA mice for at least 7 days. The trans­
duced cells expressed immunoreactive and bioactive 
HuIL-IRa in the knee joint, and produced sufficient 
amounts to block the effect of 1 ng of recombinant 
murine IL-la on chondrocyte proteoglycan synthesis. 
The onset of CIA was almost completely prevented in 
knee joints containing HuIL-lRa-producing cells, 
whereas joints containing normal cells showed severe 
inflammation and destruction of cartilage. Moreover, 
onset of CIA in the draining joints (ipsilateral paws) of 
the HuIL-IRa gene-bearing knees was also prevented.
Conclusion. Local production of HuIL- I Ra in the 
knee was able to ameliorate the effects of IL-1 on 
cartilage and could prevent the onset of CIA not only in
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that knee, but also in the “draining” paw. This indicates 
the feasibility of gene transfer as a therapeutic ap­
proach to modulating arthritis.
Rheumatoid arthritis (RA) is an autoimmune 
disease characterized by progressive joint destruction 
and immobility. Prevention of cartilage erosion and 
dysfunction would be of great therapeutic benefit to 
patients. There is convincing evidence that the cytokines 
tumor necrosis factor a (TNFa) and interleukin-1 (IL-1)
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this model and that systemic treatment with IL-IRa 
provides impressive protection (8).
In the present study we investigated the efficacy 
of local gene therapy in the murine knee joint using 
HuIL-lRa-transduced NIH/3T3 cells. The class I major 
histocompatibility complex antigens on NIH/3T3 cells 
are identical to those in the DBA/1 inbred mouse strain, 
and this strain is therefore suitable as a host for trans­
plantation of 3T3 cells (18). Prolonged expression of 
HuIL-lRa sufficient to neutralize nanogram quantities 
of IL-1 was obtained in the synovial tissue. Onset of CIA 
could be fully prevented in the transplanted joint. Re­
markably, the “draining” paw of the knee transplanted 
with HuIL-Ra-producing cells was also protected from 
CIA, whereas the remote paws were unaffected and 
showed full-blown arthritis. This suggests either a linked 
onset of arthritis between knee and paw, probably 
through IL-1, or an overflow of HuIL-lRa from the knee 
to the nearby joints.
MATERIALS AND METHODS
Production of HuIL-lRa-producing 3T3 cells. The
3T3 cells were infected with the retroviral vector pMFG-IRAP 
(kindly provided by Dr. C. Evans, Pittsburgh, PA) as described 
elsewhere (15). Briefly, 3T3 cells were grown to —75% conflu­
ence in a 25-cm2 flask. Medium was removed and replaced 
with 1 ml of viral suspension in the presence of 8 ¡jlg/ml 
Polybrene. After 2 hours, 3 ml of medium was added and the 
cultures were incubated for 72 hours. Clones were obtained by 
limiting dilution and selected for HuIL-lRa secretion, using a 
radioimmunoassay (RIA). Two clones were selected for their 
high HulL-Ra production (2.1 /xg/Hf cells/24 hours and 5 /u-g/l O6 
cells/24 hours). Evidence that 3T3 cells are suitable vehicles for 
protective gene constructs is provided by the fact that production 
of proinflammatory cytokines such as IL-6, TNFcv, or IL-1 could
by bioassay or by reverse transcription-not be
polymerase chain reaction. Furthermore, transplantation of 2 X 
10 normal 3T3 cells to knees of normal C57B1/6 mice did not 
elicit an inflammatory reaction (followup of 1 week).
HuIL-lRa radioimmunoassay. HuIL-lRa was mea­
sured by RIA according to the method of Poutsiaka et al (19). 
Briefly, diluted polyclonal rabbit anti-HulL-IRa was added to 
the samples, and they were kept overnight at room tempera­
ture. Iodinated IL-IRa was added to each sample, followed by 
incubation overnight at room temperature. Immunoprecipi- 
tates were formed by the addition of sheep anti-rabbit IgG and 
polyethylene glycol, at respective final concentrations of 1% 
and 3%. After 1 hour at room temperature, immunoprecipi- 
tates were recovered and counted.
IiuIL-lRa immunohistochemistry studies. Whole 
mouse knees were snap frozen in liquid nitrogen. Sections 
were attached to adhesive tape (20), fixed in 4% paraformal­
dehyde in phosphate buffered saline (PBS) for 10 minutes, and 
either used immediately or dried and stored at — 70°C in an 
airtight container. Sections were rehydrated in PBS and incu-
bated for 2 minutes in 0.2% Triton X-100 to permeabilize cell 
membranes. Endogenous peroxidase was blocked by incuba­
tion in 0.5% UUO-, in PBS. After a further wash in PBS, 
sections were incubated overnight with polyclonal rabbit anti- 
HuIL-lRa antibodies (Genzyme, Cambridge, MA) diluted 
1:500 in 4% nonfat dry milk in PBS. Sections were washed and 
incubated for 1 hour with goat anti-rabbit biotinylated anti­
bodies (Vector, Burlingame, CA). Secondary antibodies were 
detected with an avidin-biotin-peroxidase complex (Vec- 
tastain ABC Kit; Vector). After washing again in PBS, perox­
idase activity was detected by 10-minute incubation in 0.5 
mg/ml 3.3'-diaminobenzidine tetrahydrochloride (Sigma, St. 
Louis, MO) dissolved in 0.05M Tris HC1 buffer, pH 7.6, 
containing 0.02% H20 2. Finally, sections were counterstained 
with Mayer’s hematoxylin and embedded in gelatin-glycerin.
Induction of zymosan-induced arthritis (ZIA) and 
treatment protocol. A homogeneous suspension of 30 mg
A (Saccharomyces cerevisiae) dissolved in 1 ml 
endotoxin-free saline was obtained by boiling twice followed by 
sonic émulsification. Arthritis was induced by intraarticular 
injection of 180 /xg zymosan into the knee joint. HuIL-lRa- 
producing cells or 3T3 cells (2 X 105) were injected intra- 
articularly into the knee joint 2 days before induction of ZIA. 
Two days after induction of ZIA, knee joint inflammation was 
assessed by 'Wrntechnetium pertechnetate uptake, and proteo­
glycan (PG) synthesis was determined by in vitro 35S-sulfate 
incorporation in patellae.
Assessment of knee joint swelling. Joint swelling was 
quantified by 99mTc uptake as previously described (6). Briefly, 
10 ju-Ci WmTc in 0,2 ml saline was injected subcutaneously in 
the neck region, and mice were sedated by intraperitoneal 
injection of 4.5% chloral hydrate (0.1 ml/10 mg body weight). 
Accumulation of the isotope in the knee was determined after 
30 minutes by external gamma counting.
Induction of CIA and treatment protocol. DBA/1 mice, 
age 9-10 weeks at the start of experiments, were immunized 
intradermally at the base of the tail with bovine type II 
collagen (100 fxg) emulsified in Freund’s complete adjuvant 
(Difco, Detroit, MI). On day 21, the animals were boosted with 
an intraperitoneal injection of 100 /xg type II collagen. Gradual 
onset of arthritis normally starts approximately 4 weeks after 
immunization. In the first experiment, 10 mice that did not yet 
have any macroscopic signs of arthritis were selected at 32 days 
after the initial immunization. These mice received 2 X 105 
HuIL-lRa-producing cells in the right knee and 2 X 105 
normal NIH/3T3 cells in the left knee. In the second experi­
ment, we took mice before arthritis onset, 23 days after the 
initial immunization, and divided them 
either 2 X 105 normal 3T3 cells (n = 10), HuIL-l Ra cells (5
/xg/10 \s ; n a HuIL-lRa-
= 9) in the
= 10), or
producing cell-line (2.1 /xg/10(’ cells/24 hours; n 
right knee joint. Saline was injected into the left knee joint. 
CIA development in the first experiment was evaluated by 
assessment of knee swelling on day 4 and macroscopic scoring 
of the draining paws and histologic analysis on day 5. CIA 
development in the second experiment was assessed by mac­
roscopic scoring of the draining paws and histologic analysis of 
the knees on day 5.
Macroscopic scoring of CIA. Erythema and swelling of 
the paws were scored on a 0-2 scale, with a maximum score of 
2 for each paw. Scoring was done by 2 independent observers,
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and the mean scores from the 2 observers were used for 
analyses.
Assessment of PG synthesis. Patellae were dissected so 
as to minimize the amount of adjoining synovium, tendon, and 
muscle, and placed in 200 jtxl RPMI-HEPES medium (Life 
Technologies, Breda, The Netherlands) supplemented with 
entamicin (50 mg/liter), L-glutamine (2 mM), and 40 ju,Ci 
35S-sulfate/2 ml. After a 3-hour incubation, patellae were fixed 
in 10% formalin, decalcified in formic acid (4%), punched out, 
and dissolved in 0.5 ml Lumasolve (Omnilab, Breda, The
« m  *
Netherlands). The * * S content of each patella was measured by 
liquid scintillation counting and expressed as counts per minute.
To determine the in vitro potency of recombinant 
HuIL-IRa (rHuIL-IRa), patellae from normal C57B1/6 mice 
were isolated. PG synthesis was measured after incubation of 
the patellae with or without 1 ng/ml or 10 ng/ml recombinant 
murine IL -la  (rMuIL-la) for 48 hours in medium supple­
mented with 0.5 /u-g/ml insulin-like growth factor in the pres­
ence of various amounts of rHuIL-IRa (generously provided 
by Amgen, Boulder, CO). After 48 hours, the 35S-sulfate 
content of the patellae was measured as described above. PG 
breakdown was measured by first prelabeling the patellae as 
described above, followed by a 48-hour incubation in medium 
in the presence of 10 ng/ml rM uIL-la and various concentra­
tions of rHuIL-IRa. The 35S-sulfate content of the patellae was 
again measured as described above. Data are shown as the 
percentage of 35S-sulfate incorporation in the right (experi­
mental) knee compared with the left (control) knee.
Histologic processing and analysis of knee joints. 
Knee joints were dissected, fixed, decalcified, dehydrated, and 
embedded in paraffin. Standard frontal sections of 7 ¡xm were 
prepared, stained with Safranin O, and counterstained with 
fast green. Cartilage depletion was visualized by diminished 
staining of the matrix and scored arbitrarily as 0 when normal 
or 1-3 according to the degree of depletion (loss of staining). 
Exudate was scored arbitrarily as 0 when no cells were present 
in the joint space or 1-3 according to the cell content of the 
joint space (predominantly polymorphonuclear cells).
For autoradiography, 35S-sulfate (50 /xCi per animal) 
was administered to the animals shortly (2 hours) before killing 
and knee and ankle joints prepared for histologic study. 
Sections were mounted on gelatin-coated slides, dipped in K5 
emulsion (Ilford, Basildon, UK) and developed 
weeks (21).
2-4
i »  | mStatistical analysis. Data are expressed as the mean 
SD. Statistical analyses were performed using the 2-sample 
/-test for parametric data, and the Wilcoxon signed rank test 
for nonparametric data.
RESULTS
Potency of HuIL-IRa in blocking effects of IL-1 
on patellae in vitro. To determine the amount of rHuIL- 
lRa needed to completely block rMuIL-la, patellae 
from normal C57B1/6 mice were isolated and cultured 
with saline, 1 ng/ml rMuIL-la, or 10 ng/ml rMuIL-la, 
either alone or together with various concentrations of 
rHuIL-IRa (Table 1). From these experiments, it was 
evident that in vitro, at least a 1,000-fold excess of
Table 1. Potency of HuIL-IRA in blocking the effects of IL-l on 
mouse patellae in vitro*
Concentration
%  inhibition of PG synthesis
of rHuIL-IRa, 1 ng/ml 10 ng/ml % PG
ng/ml rMuIL-la rMuIL-1« breakdown
0 53 64 36
1.00 47 ND 35
300 24 ND ND
1,000 8 60 34
10,000 ND 10 2
* Proteoglycan (PG) synthesis was determined in normal patellae (n =  
7) cultured for 48 hours in the presence of 1 ng/ml or 10 ng/ml 
recombinant mouse interleukin-1« (rMuIL-1 a) with various concen­
trations of recombinant human IL-1 receptor antagonist (rHuIL-IRa), 
followed by a 3-hour incubation with S 0 4. Breakdown of PG was
measured in • SO.(-prelabeled patellae, by 48-hour incubation with 10 
ng/ml rMuIL-1« and various concentrations of HuIL-IRa, Inhibition 
of PG synthesis was measured as the percent reduction in ,vSO^ 
incorporation compared with patellae incubated without rMuIL-la or 
HuIL-IRa. ND = not done.
rHuIL-IRa over rMuIL-la is needed to completely 
block the effects of rMuIL-la on PG synthesis and 
breakdown in patellar cartilage.
In vivo application of HuIL-IRa by transplanta­
tion of HuIL-lRa-producing 3T3 cells to knee joints. 
We examined, by immunohistochemistry, local produc­
tion of HuIL-IRa after transplantation of HuIL-lRa- 
producing 3T3 cells to C57B1/6 and DBA/1 mice. In 
C57B1/6 mice, HuIL-lRa-containing cells were retained 
in the knees for at least 7 days (Figure 1). No signs of 
inflammation (granulocyte influx) were observed, but a
slight thickening of the synovial lining was seen, 
swelling as measured by t)t;mTc uptake was negligible, 
and cartilage damage or PG depletion was not observed 
on histologic sections. Since the CIA experiments had to 
be performed in susceptible DBA/1 mice, we also in­
jected 3T3 cells or HuIL-lRa-producing cells into the 
knee joints of mice of this strain. In none of the animals 
was significant joint pathology noted on day 5, and local 
HuIL-IRa production was similar compared with the
2,10 pattern seen in %i\
inhibition of PG synthesis in
To investigate whether the immunoreactive 
HuIL-IRa was bioactive, HuIL-lRa-producing 
were injected into knee joints 1 day before the intra 
articular injection of 1 ng or 10 ng rMuIL-1.
blocked
cartilage induced by 1 ng rMuIL-1, whereas 
of 10 ng rMuIL-1 could not be blocked (Figure 2). Since 
the amount of IL-1 produced in arthritic joints does not 
exceed the nanogram level (22), these cells 
quently used in arthritis models.
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Figure 1.
2 X 105 cells into a murine knee joint. A, Normal 3T3 cells. B, HuIL-IRa
F =  femur.
producing cells. Cells adjacent to the lining are positive for HuIL-IRa.
Effect of HuIL-lRa-producing cells on ZIA- 
induced PG synthesis inhibition. HuIL-lRa-producing 
cells (2 X 105) were injected intraarticularly into the 
mouse knees, followed 2 days later by 180 /xg zymosan. 
PG synthesis by patellar chondrocytes was determined 
on day 4. Intraarticular injection of normal 3T3 cells did 
not have an effect on the inhibition of cartilage PG
35
120
Yo of SO 4 incorporation
1.1 t
□  3T3 control ■HuiL-1Ra
100
80
60
40
20
0
1 ng IL-1 10  ng IL-1
Figure 2. Expression of human interleukin-1 receptor antagonist 
(HuIL-IRa) in the knee counteracts the effect of intraarticular injec­
tion of recombinant murine IL-1 a (rMuIL-la) on proteoglycan syn-
\sis.
the left knee, 2 x  105 normal 3T3 or hIL-lRa-producing cells were 
injected intraarticularly into the right knee. Two days after the 
injection, patellae were isolated and incubated for 3 hours with 35S 0 4, 
and the ■,5S 0 4 content in the patellae was measured (counts per 
minute) (n = 5). Values are the mean and SD percentage of ri5SO
content in 5fi
4
P  <
0.01 compared with the 3T3 control, as determined by 2-sample Mest.
synthesis in ZIA. The HuIL-lRa-producing cells signif­
icantly ameliorated PG synthesis, from 52% to 73% of 
normal (Figure 3). Histologic analysis revealed a similar 
infiltrate in the knees treated with normal 3T3 and those 
treated with HuIL-1 Ra-producing cells (results not
35Vo of SO. incoporation
100
80
60
40
20
0
*
- r -  I  n , » « »  « f t
ZIA control 3T3 control HulL-1 Ra
Figure 3. Effect of local human interleukin-1 antagonist
(HuIL-IRa) production on inhibition of proteoglycan production in 
patellae with zymosan-induced arthritis (ZIA). Human IL-1 Ra- 
producing cells (n =  22) or normal 3T3 cells (n =  20) (each at 2 X 1()5) 
were injected into the right knee joint. Control right knees (n = 15) 
received no injection. Two days later, 180 ¡xg zymosan was injected
After 2 days, proteoglycan synthesis in the patellae was assessed by ex 
vivo measurement of 35S 0 4 incorporation (counts per minute). Values 
are the mean and SD percentage of 35S 0 4
compared with the left patellae. * = p  <  0.01 compared with the 3T3 
control, as determined by 2-sample t-test.
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Table 2. Histologic evaluation of collagen-induced arthritis in mouse 
knees transplanted with 2 X 10s 3T3 cells or 1 of 2 different 
I-IuIL-lRA-producing 3T3 cell lines’*
Transplanted
Histologic score
Arthritis
cell line Infiltrate Exudate PG loss$ incidence
Experiment 1 
3T3 1.9 ±  1.5 1.9 ±  1.5 2.0 ±  1.4 7/10
HuIL-IRa (1) 0.4 ±  1.0 0.3 ±  1.0 0.5 ±  1.0 1/10
Experiment 2
Saline 1.4 ±  1.4 1.6 ±  1.3 1.3 ± 1 . 4 13/29
3T3 2.7 ±  1.0 2.8 ±  0.8 2.5 ±  0.9 9/10
HuIL-IRa (1) 0.7 ± Q.9§ 0.8 ±  0.8§ 0.5 ±  1.0§ 1/10
HuIL-IRa (2) 1.1 ±  1.1 § 0.7 ±  0.9§ 0.8 ±  1.1§ 1/9
*
c
sections were stained with Safranin O. Histologic data are expressed as 
the mean ± SD. 3T3 = normal 3T3 cells; HuIL-IRa (1) 
producing 5 /¿g HuIL-lRa/106 cells/24 hours; saline 
knees from all 3 groups; HuIL-IRa (2) =
/xg/HuIL-lRa/10f’ cells/24 hours. See Table 1 for other definitions, 
t  Exudate was scored arbitrarily as 0 when no cells were present in the 
joint space or 1-3 according to the cell content of the joint space 
(predominantly polymorphonuclear cells).
$ PG loss of femur and patellar cartilage. Cartilage PG depletion was
0 when normal or 1-3 according to the degree of loss of Safranin O
staining.
§ P  <  0.05 versus 3T3 group, by Wilcoxon signed rank test.
shown), consistent with earlier observations that PG 
synthesis inhibition, but not synovial infiltration, is IL-1 
dependent in this model (7).
Effect of the transplanted HuIL-lRa-producing 
cells on CIA in the knee joint. Onset of murine CIA 
generally occurs approximately 4 -6  weeks after the first 
immunization and has been shown to be IL-1 dependent 
(4,5,8). In the first experiment, 10 type II collagen-
immunized mice without signs of arthritis on day 32 were 
selected. Cells producing HuIL-IRa were injected into 
the right knee joints, whereas 3T3 cells injected into the 
left knee joints served as controls. Knee joint swelling 
was measured by " mTc uptake 4 days after transplanta­
tion of the cells. The mean ± SD left/right ratio for the 
10 mice was 1.72 ±  0.37. In only 1 mouse did both knees 
appear equally swollen; but in all other mice 
knee was swollen
scopically normal. Thus, in 9 of 10 mice,
after transplantation of the cells, knee joint sections 
were prepared for histologic study and autoradiography 
was performed to measure cartilage chondrocyte func-
4 incorpo­
ration in cartilage, whereas noninflamed knees had 
normal 35SQ4 incorporation. Occurrence of marked cell 
influx and major tissue destruction was seen in 7 of 10 
left knee joints transplanted with normal 3T3 cells, 
versus only 1 of 10 of the right knee joints transplanted 
with HuIL-lRa-producing cells. Affected knees had 
severe histologic scores (>2) for infiltrate, exudate, and 
PG loss, resembling classic CIA.
In a second experiment, mice were selected just 
before the onset of CIA, on day 23 after the initial 
immunization. In this experiment, 3T3 cells or 2 differ­
ent HuIL-lRa-producing clones were transplanted into
knee joints. Five days later, knee joints were scored
ular injection), 50% of the right and left knee joints
-1 Ra
¡-prone mouse 
. P
* * 2 X 10 s
patella; F =  femur; GP ^ < n « l u t t f i à i f
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Figure 5. Occurrence of arthritis in the knees of type II collagen- 
immunized mice transplanted with human interleukin-1 receptor an­
tagonist (HuIL-lRa)-producing 3T3 cells (second experiment). In the
untreated group (n 8 ) ,  mice vShow ed normal development of
collagen-induced arthritis in the knees. In the other 3 groups, cells 
were transplanted into the right knee joint and saline was injected into 
the left knee joint. Values are the means. 3T3 = normal 3T3 cells (n =  
10); HulL-IRa (1) = 3T3 cells producing 5 ¡xg HuIL-lRa/106 cells/24 
hours (n = 10); HulL-IRa (2) =  3T3 cells pi'oducing 2.1 ¡xg HuIL- 
lRa/106 cells/24 hours (n =  9).
developed arthritis (Figure 5). Occurrence of arthritis 
was enhanced in the 3T3-transplanted knees (90%). In 
the HuIL-lRa-transplanted knees, occurrence of arthri­
tis was markedly decreased, to 10% (5 /mg HuIL-lRa/106 
cells/24 hours) and 22% (2.1 /xg HuIL-lRa/106 cells/24 
hours) (Figure 5). The left, saline-injected knees from all 
3 treatment groups were comparable with those from the 
untreated group, suggesting that HulL-IRa expression 
in the right knee had no effect on the contralateral 
saline-injected knee. Histologic examination showed 
marked protection of the knee joints transplanted with 
either of the HuIL-lRa-producing cell lines compared 
with the knee joints transplanted with normal 3T3 cells, 
with respect to exudate, infiltrate, and PG loss (Table 2). 
The contralateral saline-injected knees from all 3 groups 
all developed CIA and had similar scores for infiltrate, 
exudate, and PG depletion of cartilage.
Effect of HulL-IRa expression on draining and 
remote paws. Human IL-IRa expression in the knee 
seemed to also have a positive effect on the draining 
paws. To further assess this phenomenon, paws were 
macroscopically scored at the same time points as histo­
logic specimens were obtained from the knees. In the 
second experiment, 50% of the untreated group devel­
oped arthritis in the right and left paws (Figure 6). 
Expression was slightly enhanced in the draining paws 
from the 3T3-transplanted knees (70%). In contrast, in
Figure 6. Occurrence of arthritis in the paws of type II collagen- 
immunized mice transplanted with HuIL-lRa-producing 3T3 cells 
(second experiment). In the untreated group (n = 8), mice showed 
normal development of collagen-induced arthritis in the paws. In the 
other 3 groups, cells were transplanted into the right knee joint and 
saline was injected into the left knee joint. Values are the means. See
Figure 5 for definitions.
the draining paws from the HuIL-lRa-transplanted 
knees, the occurrence of arthritis was markedly de­
creased, to 10% (5 jag HuIL-lRa/106 cells/24 hours) and 
11% (2.1 /xg HuIL-lRa/106 cells/24 hours) (Figure 6). 
The draining paws of the contralateral (knees
injected with saline) from all 3 groups showed an 
arthritis incidence comparable with that found in the 
untreated group, demonstrating that HulL-IRa expres­
sion in the right knee had no effect on the contralateral 
paws. Occurrence of linkage between arthritis in the 
knee and paw of one leg was further analyzed. Either
preferential expression in both ind (3T3
group) or dominant absence at both sites (the 2 HuIL-
Table 3. Linkage between the development of collagen-induced
arthritis in the knee and the 
in the paw of the same leg*
ent of collagen-induced arthritis
Cell line nf
Limb or limbs, %  affected
Knee 
and paw Only knee Only paw Neither
3T3 20 70 10 5 15
HulL-IRa (1) 20 15 0 0 85
HulL-IRa (2) 9 11 11 0 78
* Data from experiments 1 and 2 are combined. 3T3 = normal 3T3 
cells; HulL-IRa (1) = 3T3 cells producing 5 /xg human interleukin-1 
receptor antagonist (HuIL-lRa)/106 cells/24 hours, transplanted into 
the knee; I-IuIL-lRa (2) = 3T3 cells producing 2.1 ¡xg HuIL-lRa/10h 
cells/24 hours, transplanted into the knee, 
t  Number of legs evaluated, experiments 1 and 2 combined,
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IRa groups) was noted (Table 3), whereas selective 
expression either in knee or in paw was rarely seen.
DISCUSSION
We used the ex vivo method of gene transfer as 
described by Bandara et al (15) to obtain local and 
sustained expression of HuIL-IRa in the knee. It was 
found that this approach prevented the onset of CIA not 
only in that knee, but also in the nearby, draining paw. 
Contralateral knee and paw joints were not protected.
Control NIH/3T3 not expressing HuIL-IRa en­
hanced, rather than suppressed, the onset of arthritis.
Using immunohistochemistry methods, we have
shown that the transduced 
into the knee cavity continue producing the HuIL-IRa 
protein for at least 7 days. Furthermore, transplantation 
of 2 X 105 HuIL-lRa-producing cells into the knee joint 
could completely block the effects of an intraarticular 
injection of 1 ng rMuIL-la on patellar PG synthesis. 
Since it is known from previous studies that the peak 
levels of IL-1 produced by the inflamed synovial tissue 
after onset of arthritis do not exceed the nanogram level, 
the selected HuIL-lRa-producing cells are sufficiently 
potent.
One concern about application of local gene 
therapy is a potential disturbing effect of the inflamma­
tory process on protein production and, for the ex vivo 
method in particular, the nonspecific effect of the trans­
planted cells on the inflammation process. To evaluate 
this we used the model of ZIA, in which we demon­
strated previously that the inhibition of chondrocyte PG 
synthesis could be completely prevented, but that the 
joint swelling was only marginally suppressed, with neu­
tralizing anti-IL-1 antibodies (7). In the present study 
we noted that local expression of HuIL-IRa in the knee 
during ZIA barely affected joint swelling (yi)mTc up­
take), consistent with IL-1 independence 
of cartilage PG synthesis was clearly i 
more, transplantation of NIH/3T3 cells
ZIA-related joint mg or a
inhibition. These observations demonstr that the cells
do not influence ZIA and HuIL-IRa is
produced during the inflammation. In comparison with 
our in vitro blocking studies (Table 1), we can extrapo­
late that we must have achieved at least a 300-fold excess 
of HuIL-IRa above local murine IL-1 levels to explain
the positive effect on PG This indirectly
proves that the transplanted cells still produce consider­
able amounts of HuIL-IRa under conditions of
inflammation.
In the model of murine collagen arthritis, both
joint inflammation and cartilage destruction are IL-1 
dependent (4,5,8). Consistent with this, the local expres­
sion of HuIL-IRa prevented both events. Recent studies 
with IL-1 ^ -converting enzyme inhibitors (23) as well as 
observations in IL-10 knockout mice confirm this strong 
IL-1 dependence. Bandera et al (15) have shown, in 
studies of rabbits, that autografted synoviocytes exhibit a 
much longer intraarticular transgene expression as com­
pared with allografted cells, 
compatible with the DBA/1
of local -IRa transgene
to 5 days, which excludes the possibility that the
were flawed by graft We have not yet
or
but we are currently 
autologous synovial fibroblast cell
a DBA/1 
for this purpose. 
The fact that we found similar effects with 2 different 
HuIL-lRa-producing cell lines of comparable potency 
provides further proof that the observed suppression of 
arthritis is probably not due to an aberrant character of 
the cell lines used.
Two earlier publications, by Makarov et al (17) 
and Otani et al (16), have shown the potential of the ex 
vivo method in, respectively, antigen-induced arthritis in 
rabbits and bacterial cell wall-induced arthritis in rats. 
Due to the monarthritic nature of these experimental 
arthritis models, those investigators could not determine
the of HuIL-IRa production in the on
nearby and more remote joints. The polyarthritic nature
of the CIA model allowed us to obtain such information. 
We observed that local HuIL-IRa production in the
not only prevented onset of CIA in that knee, but
of CIA in the draining paw,
contralateral leg was 
seems to link with previous work (24), in which we
that expression of collagen arthritis in a partic-
u I a v can be by local
cytokine-generating stimuli such as zymosan, and that
high concomitant occur l in the
draining paw but not in the remote joints. Furthermore, 
Staite et al (11) have shown that IL-1 administered in 
the knee augments a local inflammatory response of 
methylated bovine serum albumin at that site, but also 
affects the ipsilateral paw. These data suggesting cou­
pling of arthritic processes in nearby joints may indicate 
that gene therapy applied to a larger joint could exert 
protective effects in smaller joints of hands or feet.
It is debatable whether the ex vivo method is the
ideal gene therapy technique. In
at
it is labor intensive,
with local 
vectors or
4
C
change during the transfer from to culture
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conditions and back. However, cell targeting is possible 
in vitro, and some of the adenoviral vectors show 
inflammatory properties and need further constructive 
cleaning. The present data provide good evidence for 
the possibilities of local expression of therapeutic pro­
teins for treatment of arthritis. We have shown that 
transplantation of cells producing HuIL-IRa to the knee 
cavity can protect articular cartilage against IL-1- 
induced inhibition of PG synthesis and can prevent onset 
of CIA not only in the transplanted knees, but also in the 
draining paws. It is expected that better vectors will 
become available in the near future to optimize expres­
sion and targeting to relevant cells and tissues of the 
joint.
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